综合数据平台与糖尿病成年人的饮食管理相结合的应用:一项前性随机对照试验
Xiyu Liu1, Xiaohong Wang1, Mengxun Xie1
1Dongyang Hospital of Wenzhou Medical University, Dongyang, Zhejiang, China.
Journal of diabetes investigation
|August 22, 2024
概括
一个集成的数据平台与饮食管理改善了2型糖尿病控制. 这种方法,特别是塞马格卢提德,在超重或肥胖患者中显著降低了体重.
科学领域:
- 内分泌学和新陈代谢学
- 数字健康数字健康
- 临床营养学 临床营养学
背景情况:
- 2型糖尿病的管理需要持续监测和个性化干预.
- 传统的护理模式可能无法充分利用技术,以获得最佳的患者结果.
- 综合数据平台为改善糖尿病护理提供提供了潜力.
研究的目的:
- 评估基于云计算的综合数据平台与2型糖尿病成年人的饮食管理相结合的有效性.
- 评估这种综合方法对血糖控制和体重的影响.
- 探索塞马格卢提德与超重/肥胖患者体重管理平台的作用.
主要方法:
- 一项随机对照试验,涉及180名2型糖尿病患者.
- 对照组 (标准护理) 与实验组 (综合数据平台,饮食管理和个性化视频) 的比较.
- 主要终点:12周后HbA1c和体重的变化.
主要成果:
- 与对照组相比,实验组显示HbA1c水平明显降低 (6.9%与7.4%相比),并且达到目标血糖控制的比率更高.
- 实验组中的超重和肥胖患者经历了显著的体重减轻和BMI降低.
- 与平台一起使用塞马格卢提德的患者实现了最显著的减肥 (13.4%在12周内).
结论:
- 综合数据平台与个性化糖尿病教育是2型糖尿病的有效管理策略.
- 结合平台,饮食管理和西马格卢提德,可提高患有糖尿病的超重或肥胖成人减肥的效果.
- 数字健康解决方案在改善慢性疾病管理方面表现有前途.
相关概念视频
Diabetes: Management and Pharmacotherapy
245
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
245
Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
Insulin: Dosing Regimen and Adverse Effects
161
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
161
Diabetes Mellitus: Overview and Type I Subtype
2.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.5K
Diabetes: Symptoms, Diagnosis, and Complications
520
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
520
Dipeptidyl Peptidase 4 Inhibitors
179
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
179


